Belantamab mafodotin (belamaf) is the first antibody-drug conjugate directed against B-cell maturation antigen (BCMA) available for use in patients with multiple myeloma (MM) [1,2]. This evidence concerns the gene TNFRSF17 and Miyoshi myopathy.